Sunmnary The effect of epidermal growth factor (EGF) on the biological behaviour of human tumours in vivo is still controversial. We investigated the effect of EGF on the growth of an EGF receptor-hyperproducing human epidermoid carcinoma, A431 tumour, and on a human small-cell lung carcinoma, H69 
Epidermal growth factor (EGF) was originally isolated from a mouse submandibular gland (Carpenter and Cohen, 1979) and has various biological actions as a potent mitogen for the epidermis and several epithelial tissues (Hollenberg, 1979; Das, 1982; Fox et al., 1982) . Many transformed cells produce EGF-associated growth factors, such as transforming growth factor alpha (TGF-a) which interacts with EGF receptors, and TGF-P (Sporn and Roberts, 1984) . Overexpression of EGF receptor has been shown to occur at a high incidence both in primary squamous cell carcinomas and in established cell lines such as A431 (Ozanne et al., 1985; Gullick et al., 1986; Ozawa et al., 1987a) . The v-erbB oncogene of avian erythroblastosis virus originates from part of the host cell EGF receptor gene (Ullrich et al., 1984; Shimizu et al., 1985) . Thus, the involvement of the EGF and its receptors in transformation and progression of malignant cells has been suggested. Although there are several studies investigating the effect of EGF on the growth of EGF receptorhyperproducing cell lines in vitro and in vivo (Gill and Lazer, 1981; Kamata et al., 1986; Ozawa et al., 1987b; Amagase et al., 1990; Murayama, 1990) , the physiological role of EGF on the EGF receptor-hyperproducing tumour growth remains obscure and still controversial. Tsutsumi et al. (1987a) demonstrated that EGF at the physiological level promotes the implantation and growth of spontaneous mouse mammary tumours in female nude mice. There have been no previous studies on the effect of changes in plasma EGF levels within the physiological range on the growth of human tumours which have various EGF receptor levels. The mouse submandibular gland is a rich source of EGF, and it is well established that sialoadenectomy lowers the circulating level of EGF in mice (Tsutsumi et al., 1986 (Tsutsumi et al., , 1987b . In this study, we investigated the effect of endogenous EGF on EGFhyperproducing human tumours using sialoadenectomised mice. 
Materials and methods

Materials
Results
Effect of sialex on plasma EGF levels The plasma EGF concentration in the sialex mice (0.11 ± 0.03 ng ml-1) was significantly lower than that in the sham-operated mice (2.15 ± 1.23 ng ml-') (P <0.05) ( Figure  1 ). The plasma EGF levels in the sialex and sham-operated mice were significantly increased by continuous EGF administration. After the exogenous EGF replacement, there was no significant difference between the plasma EGF levels of the sialex (7.90 ± 1.81 ng ml -') and sham-operated mice (8.67 ± 1.54 ng ml -') ( Figure 1 ). Figure 3 . There was no significant difference in estimated tumour weight of these tumours among the four groups. These findings on estimated tumour growth in A431 and H69 tumours were confirmed by weighing the tumours after they were removed (Table I) . 2.0± 1.9
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2.2± 1.7 aBrdU labelling index = (Number of labelled tumour cell nuclei/Number of tumour cell nuclei counted) x 100. **P<0.05. , 1989) . Previously, Lee et al. (1990) have demonstrated that EGF inhibits anchorage-dependent growth but stimulates anchorage-independent growth of human squamous carcinoma cell lines that overexpress EGF receptors. These studies suggest that the proliferative responses of EGF receptor-hyperproducing cells to EGF might be affected by other characteristics of cell lines and culture conditions. It seems that there are many factors which can affect the proliferative responses to EGF in vivo, such as interaction with interstitial tissues and other mediators. As Fidler (1990) demonstrated in studies on mechanisms of cancer metastasis, the outcome of metastasis depends on the interaction of metastatic cells with different organ environments. Accordingly, from this point of view, studies of 'the in vivo environment' are important for the investigation of actual phenomena in human carcinogenesis and progression.
Proliferative effect of endogenous EGF in vivo
However, the effect of EGF on the proliferation of EGF receptor-hyperproducing tumours in vivo is still complicated and controversial. Murayama (1990) has reported the growth-inhibitory effects of EGF on human breast cancer and oesophageal cancer cells transplanted into athymic mice, and proposes the efficacy of EGF therapy for human cancers with overexpression of EGF receptor. Amagase et al. (1990) observed prolongation of the survival time of mice bearing various murine syngeneic tumours as well as athymic mice bearing human xenografts. On the other hand, Ginsburg and Vonderhaar, (1985) and Ozawa et al. (1989) demonstrated that EGF promotes the growth of tumours of EGF receptorhyperproducing squamous carcinoma cells.
The studies cited above indicate that differences in the responses of EGF receptor-hyperproducing tumours to exogenous EGF might depend on the doses and routes of EGF administration. In this study, we have demonstrated the proliferative effects of endogenous EGF at a physiological level on the EGF receptor-hyperproducing human squamous carcinoma cells transplanted to athymic mice. The growthinhibitory effect of sialex and growth-stimulatory effect of exogenous continuous EGF administration on EGF receptorhyperproducing A431 tumours and the lack of an effect on EGF receptor-undetectable H69 tumours clearly imply a role of the EGF-EGF receptor system in the proliferation of EGF receptor-overexpressing human tumours. On the other hand, when EGF was administered as a local bolus injection directly into the tumour (Murayama, 1990) , this induced down-regulation of the EGF receptor and did not reflect the physiological role of endogenous EGF. Also, Amagase et al. (1990) noted that prolongation of survival times by EGF is independent of the number of EGF receptors on tumour cells. The growth-inhibitory effects observed in these studies apparently depend on mechanisms other than the EGF-EGF receptor system. Tsutsumi et al. (1987a) , however, demonstrated the promoting effect of a physiological level of EGF on the implantation and growth of a mouse mammary tumour in sialex nude mice. This is in agreement with our data, which are the first to demonstrate the growthpromoting effect of endogenous EGF on a human tumour using a sialex nude mice model.
In this study, the BrdU labelling indices in these tumours suggest that EGF promotes the mitotic activity of EGF receptor-hyperproducing tumours. Changes in tumour weight and BrdU labelling indices corresponded to the plasma EGF level only in the EGF receptor-hyperproducing A43 1 cell tumour. It is conceivable that physiological levels of EGF contribute to the activation of the signal transduction pathway that initiates cell proliferation.
Previously, squamous carcinomas of the neck, lung, gingiva and oesophagus were found to express elevated levels of EGF receptors at high frequency (Ozanne et al., 1985; Gullick et al., 1986; Ozawa et al., 1987a) . Notably, in oesophageal squamous cell carcinoma, a significant correlation between the EGF receptor overexpression and poor prognosis of the disease has been reported . Amplification of the EGF receptor gene, c-erbB, was significantly correlated with lymph node metastasis and poorer prognosis in patients with oesophageal squamous cell carcinoma (Kitagawa et al., 1992) . Moreover, EGF expression has been detected in several human cancer cells, including squamous cell carcinoma. Our observations in this study suggest that EGF receptor-hyperproducing carcinomas in patients have growth advantages through the EGF-EGF receptor system, including the autocrine loop.
On the basis of such findings, Hirota et al. (1989) have demonstrated the inhibitory effect of an immunotoxin, which is the conjugated form of anti-EGF receptor monoclonal antibody and plant toxin, to the A431 tumours transplanted in athymic mice as a model of the anti-EGF-EGF receptor system treatment. The findings shown in this study also are encouraging for the establishment of anti-EGF-EGF receptor system treatments for EGF receptor-hyperproducing human cancers.
